GlassScriptPhysician profile
Niraj Y Shah
NPI 1215248067
$6,193.74
in general payments reported to CMS, 2019-2025
38 companies · $360 in 2025
The $360 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,103 · 2020: $494 · 2021: $1,239 · 2022: $922 · 2023: $1,415 · 2024: $661 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,435.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,126.32 | 2020-2025 | Vraylar, Ubrelvy, Linzess |
| Nestle Healthcare Nutrition INC. | $701.04 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $625.62 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $598.70 | 2019-2022 | |
| Pfizer INC. | $565.40 | 2019-2025 | |
| Novo Nordisk INC | $336.02 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $287.08 | 2020-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $281.46 | 2019-2023 | |
| Gilead Sciences, INC. | $234.37 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $199.05 | 2019-2025 | Steglatro, Gardasil 9, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.96 | 2019-2022 | |
| Amgen INC. | $108.46 | 2019-2022 | |
| Horizon Therapeutics Plc | $99.14 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $88.29 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $86.35 | 2019-2021 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niraj Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.